Primary follicular lymphoma of the cervix uteri: a review


Creative Commons License

Korcum A. F., Karadogan I., Aksu G., Aralasmak A., Erdogan G.

ANNALS OF HEMATOLOGY, vol.86, no.9, pp.623-630, 2007 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Review
  • Volume: 86 Issue: 9
  • Publication Date: 2007
  • Doi Number: 10.1007/s00277-007-0328-0
  • Journal Name: ANNALS OF HEMATOLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.623-630
  • Keywords: primary cervix lymphoma, follicular, radiotherapy, chemotherapy, NON-HODGKINS-LYMPHOMA, ANTI-CD20 MONOCLONAL-ANTIBODY, PRIMARY MALIGNANT-LYMPHOMA, OF-THE-LITERATURE, LOW-GRADE LYMPHOMA, B-CELL LYMPHOMA, TERM-FOLLOW-UP, NEOADJUVANT CHEMOTHERAPY, RADIATION-THERAPY, PHASE-II
  • Akdeniz University Affiliated: Yes

Abstract

Primary non-Hodgkin's lymphoma of the cervix is a rare disease, of which a subgroup of follicular lymphoma constitutes only 8.5%. There is not an established treatment protocol neither for primary cervical lymphoma nor for its follicular subgroup. We presented a case with Ann Arbor stage IEA (Extra-nodal involvement and absence of weight loss, fever, night sweat) primary follicular lymphoma of the cervix. She was treated with chemotherapy followed by pelvic radiotherapy. Upon relapse with a nodal neck mass, she was treated with rituximab alone. She remained well for 23 months after rituximab. In the 39 months of follow-up, there was no evidence of disease. In the light of our case, we reviewed the reported cases of primary follicular lymphoma of the cervix while discussing their treatment protocols and the cases of primary cervix lymphoma treated with rituximab.